Coherus Oncology Inc
(STU:8C5)
€
1.073
-0.080 (-6.94%)
Market Cap: 170.27 Mil
Enterprise Value: 113.30 Mil
PE Ratio: 0
PB Ratio: 3.23
GF Score: 29/100 Coherus BioSciences Inc at UBS BioPharma Conference Transcript
Nov 09, 2023 / 04:30PM GMT
Ashwani Verma
UBS Investment Bank, Research Division - Director of Americas Equity Research & US Specialty Pharma Analyst
Okay. Good day everybody. My name is Ash Verma. I'm a SMID cap biotech and spec pharma analyst at UBS. And with me today is the Coherus team. With us, Denny Lanfear, who's the CEO; Paul Reider, Chief Commercial Officer; and Theresa Lavallee, who is the Chief Development Officer. Thanks for joining us.
Dennis M. Lanfear
Coherus BioSciences, Inc. - Chairman, President & CEO
Thank you very much for the invitation to the conference, and we're happy to talk to you today, Ash.
Ashwani Verma;Dennis M. Lanfear
UBS Investment Bank, Research Division - Director of Americas Equity Research & US Specialty Pharma Analyst;Coherus BioSciences, Inc. - Chairman, President &
Great. So just maybe start off like with a quick, very brief outline for the company for people that might not be familiar, just like take a couple of quick minutes and then to the questions.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot